{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:18:38Z","timestamp":1790133518910,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Epileptologica"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the use of appropriately selected antiseizure medications (ASMs), seizure freedom remains elusive for some patients at each treatment line, and those failing two ASMs are then classified with drug-resistant epilepsy (DRE). Living with long-term uncontrolled epilepsy can lead to discouragement and disillusionment for both people with epilepsy and clinicians. In the context of potential treatment failure, maximizing seizure control while minimizing adverse events becomes even more critical, necessitating continual symptom surveillance and consideration of therapeutic trials of ASMs where appropriate. This requires truly individualized care, and in this pursuit, physicians will encounter the diametrically opposed challenges of overtreatment (or a burdensome drug load) and therapeutic nihilism (caused by missing consideration of treatment possibilities). This paper presents a detailed review of these issues and the influence of patient- and physician-related factors. Diagnostic and treatment strategies include ensuring accurate diagnosis and epilepsy classification for optimization of ASM treatment, considering the risk-to-benefit ratio when choosing treatment, encouraging treatment adherence, considering the initiation of alternative therapies, adjusting concomitant medications when needed, maintaining awareness of variations in patient characteristics, re-framing emotions effectively, and engaging in effective communication with patients and their families. All will have to be undertaken in conjunction with cognitive and psychological approaches. Seizure freedom is an important and worthwhile goal, and patients and families should be aware that increased therapeutic options available today can make seizure freedom possible even in the context of a challenging a priori prognosis or after previous ASM failures.<\/jats:p>","DOI":"10.1186\/s42494-026-00257-3","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T23:03:21Z","timestamp":1780268601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overtreatment and therapeutic nihilism in chronic epilepsy: a call to action!"],"prefix":"10.1186","volume":"8","author":[{"given":"Bernhard J.","family":"Steinhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Paul","family":"Leach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"257_CR1","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.2147\/ndt.s84852","volume":"12","author":"L Dalic","year":"2016","unstructured":"Dalic L, Cook MJ. Managing drug-resistant epilepsy: challenges and solutions. Neuropsychiatr Dis Treat. 2016;12:2605\u201316.\u00a0","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"257_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279\u201386.\u00a0","journal-title":"JAMA Neurol"},{"issue":"8","key":"257_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/s1474-4422(23)00151-5","volume":"22","author":"E Perucca","year":"2023","unstructured":"Perucca E, Perucca P, White HS, Wirrell EC. Drug resistance in epilepsy. Lancet Neurol. 2023;22(8):723\u201334.","journal-title":"Lancet Neurol"},{"issue":"5","key":"257_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1212\/cpj.0000000000001066","volume":"11","author":"PE Penovich","year":"2021","unstructured":"Penovich PE, Stern JM, Becker DA, Long L, Santilli N, McGuire L, et al. Epilepsy treatment complacency in patients, caregivers, and health care professionals. Neurol Clin Pract. 2021;11(5):377\u201384.","journal-title":"Neurol Clin Pract"},{"key":"257_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2023.107096","volume":"190","author":"S Reeder","year":"2023","unstructured":"Reeder S, Foster E, Vishwanath S, Kwan P. Experience of waiting for seizure freedom and perception of machine learning technologies to support treatment decision: a qualitative study in adults with recent onset epilepsy. Epilepsy Res. 2023;190:107096.","journal-title":"Epilepsy Res"},{"issue":"3","key":"257_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14737175.2020.1713100","volume":"20","author":"U Amin","year":"2020","unstructured":"Amin U, Benbadis SR. Avoiding complacency when treating uncontrolled seizures: why and how? Expert Rev Neurother. 2020;20(3):227\u201335.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"257_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2009.04.007","volume":"86","author":"J McCagh","year":"2009","unstructured":"McCagh J, Fisk JE, Baker GA. Epilepsy, psychosocial and cognitive functioning. Epilepsy Res. 2009;86(1):1\u201314.","journal-title":"Epilepsy Res"},{"issue":"5","key":"257_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/j.1528-1167.2005.52404.x","volume":"46","author":"J Spatt","year":"2005","unstructured":"Spatt J, Bauer G, Baumgartner C, Feucht M, Graf M, Mamoli B, et al. Predictors for negative attitudes toward subjects with epilepsy: a representative survey in the general public in Austria. Epilepsia. 2005;46(5):736\u201342.\u00a0","journal-title":"Epilepsia"},{"issue":"3","key":"257_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/epi.12014","volume":"54","author":"E Trinka","year":"2013","unstructured":"Trinka E, Bauer G, Oberaigner W, Ndayisaba JP, Seppi K, Granbichler CA. Cause-specific mortality among patients with epilepsy: results from a 30-year cohort study. Epilepsia. 2013;54(3):495\u2013501.\u00a0","journal-title":"Epilepsia"},{"issue":"4","key":"257_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.nrl.2012.04.012","volume":"28","author":"V Villanueva","year":"2013","unstructured":"Villanueva V, Giron JM, Martin J, Hern\u00e1ndez-Pastoret LJ, Lahuerta J, Doz M, et al. Quality of life and economic impact of refractory epilepsy in Spain: the ESPERA study. Neurologia. 2013;28(4):195\u2013204.","journal-title":"Neurologia"},{"issue":"12","key":"257_CR11","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/j.1528-1167.2011.03325.x","volume":"52","author":"C Luoni","year":"2011","unstructured":"Luoni C, Bisulli F, Canevini MP, De Sarro G, Fattore C, Galimberti CA,\u00a0et al. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments: Quality of Life in Pharmacoresistant Epilepsy. Epilepsia. 2011;52(12):2181\u201391.","journal-title":"Epilepsia"},{"key":"257_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g254","volume":"348","author":"D Schmidt","year":"2014","unstructured":"Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ. 2014;348:g254.","journal-title":"BMJ"},{"issue":"11","key":"257_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1528-1167.2005.00411.x","volume":"46","author":"T Tomson","year":"2005","unstructured":"Tomson T, Walczak T, Sillanpaa M, Sander JW. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia. 2005;46(11):54\u201361.","journal-title":"Epilepsia"},{"issue":"1","key":"257_CR14","doi-asserted-by":"publisher","DOI":"10.4081\/ni.2009.e20","volume":"1","author":"R Nguyen","year":"2009","unstructured":"Nguyen R, T\u00e9llez Zenteno JF. Injuries in epilepsy: a review of its prevalence, risk factors, type of injuries and prevention. Neurol Int. 2009;1(1):e20.","journal-title":"Neurol Int"},{"issue":"6","key":"257_CR15","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1007\/s00415-017-8512-1","volume":"264","author":"L Ridsdale","year":"2017","unstructured":"Ridsdale L, Wojewodka G, Robinson E, Landau S, Noble A, Taylor S, et al. Characteristics associated with quality of life among people with drug-resistant epilepsy. J Neurol. 2017;264(6):1174\u201384.","journal-title":"J Neurol"},{"key":"257_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00414","volume":"9","author":"LM Willems","year":"2018","unstructured":"Willems LM, Watermann N, Richter S, Kay L, Hermsen AM, Knake S, et al. Incidence, risk factors and consequences of epilepsy-related injuries and accidents: a retrospective, single center study. Front Neurol. 2018;9:414.","journal-title":"Front Neurol"},{"key":"257_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eplepsyres.2014.11.003","volume":"110","author":"ME Garcia","year":"2015","unstructured":"Garcia ME, Garcia-Morales I, Gil-Nagel A. Prevalence of depressive symptoms and their impact on quality of life in patients with drug-resistant focal epilepsy (IMDYVA study). Epilepsy Res. 2015;110:157\u201365.\u00a0","journal-title":"Epilepsy Res"},{"issue":"6","key":"257_CR18","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/epi.17564","volume":"64","author":"P Klein","year":"2023","unstructured":"Klein P, Krauss GL, Steinhoff BJ, Devinsky O, Sperling MR. Failure to use new breakthrough treatments for epilepsy. Epilepsia. 2023;64(6):1458\u201365.\u00a0","journal-title":"Epilepsia"},{"key":"257_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01130-y","author":"P Klein","year":"2024","unstructured":"Klein P, Friedman D, Kwan P. Recent advances in pharmacologic treatments of drug-resistant epilepsy: breakthrough in sight. CNS Drugs. 2024;38:949\u201360.","journal-title":"CNS Drugs"},{"issue":"1","key":"257_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s0920-1211(02)00186-9","volume":"52","author":"D Schmidt","year":"2002","unstructured":"Schmidt D. Strategies to prevent overtreatment with antiepileptic drugs in patients with epilepsy. Epilepsy Res. 2002;52(1):61\u20139.","journal-title":"Epilepsy Res"},{"issue":"11","key":"257_CR21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2165\/00023210-200519110-00001","volume":"19","author":"E Perucca","year":"2005","unstructured":"Perucca E, Kwan P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs. 2005;19(11):897\u2013908.","journal-title":"CNS Drugs"},{"issue":"1","key":"257_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.18773\/austprescr.2024.001","volume":"47","author":"T Usherwood","year":"2024","unstructured":"Usherwood T. Therapeutic inertia. Aust Prescr. 2024;47(1):15\u20139.","journal-title":"Aust Prescr"},{"issue":"1","key":"257_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s0920-1211(02)00184-5","volume":"52","author":"CL Deckers","year":"2002","unstructured":"Deckers CL. Overtreatment in adults with epilepsy. Epilepsy Res. 2002;52(1):43\u201352.","journal-title":"Epilepsy Res"},{"issue":"1","key":"257_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/medu.12264","volume":"48","author":"S Mamede","year":"2014","unstructured":"Mamede S, Schmidt HG. The twin traps of overtreatment and therapeutic nihilism in clinical practice. Med Educ. 2014;48(1):34\u201343.\u00a0","journal-title":"Med Educ"},{"key":"257_CR25","volume-title":"To Err is Human: Building a Safer Health System","author":"Institute of Medicine Committee on Quality of Health Care in America","year":"2000","unstructured":"Institute of Medicine Committee on Quality of Health Care in America. To Err is Human: Building a Safer Health System. Washington (DC): National Academies Press (US); 2000."},{"issue":"2","key":"257_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1212\/01.wnl.0000049681.91195.b0","volume":"60","author":"MJ Brodie","year":"2003","unstructured":"Brodie MJ, Leach JP. Success or failure with antiepileptic drug therapy: beyond empiricism? Neurology. 2003;60(2):162\u20133.","journal-title":"Neurology"},{"issue":"7","key":"257_CR27","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.seizure.2005.08.008","volume":"14","author":"JP Leach","year":"2005","unstructured":"Leach JP, Lauder R, Nicolson A, Smith DF. Epilepsy in the UK: misdiagnosis, mistreatment, and undertreatment? The Wrexham area epilepsy project. Seizure. 2005;14(7):514\u201320.\u00a0","journal-title":"Seizure"},{"issue":"1","key":"257_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/qjmed\/92.1.15","volume":"92","author":"D Smith","year":"1999","unstructured":"Smith D, Defalla BA, Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. QJM. 1999;92(1):15\u201323.\u00a0","journal-title":"QJM"},{"issue":"1","key":"257_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0920-1211(02)00180-8","volume":"52","author":"D Schmidt","year":"2002","unstructured":"Schmidt D, Elger C, Holmes GL. Pharmacological overtreatment in epilepsy: mechanisms and management. Epilepsy Res. 2002;52(1):3\u201314.\u00a0","journal-title":"Epilepsy Res"},{"issue":"6","key":"257_CR30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.5863\/1551-6776-26.6.556","volume":"26","author":"E Wicker","year":"2021","unstructured":"Wicker E, Cole JW. Sudden unexpected death in epilepsy (SUDEP): a review of risk factors and possible interventions in children. J Pediatr Pharmacol Ther. 2021;26(6):556\u201364.\u00a0","journal-title":"J Pediatr Pharmacol Ther"},{"key":"257_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00473","volume":"8","author":"CM DeGiorgio","year":"2017","unstructured":"DeGiorgio CM, Markovic D, Mazumder R, Moseley BD. Ranking the leading risk factors for sudden unexpected death in epilepsy. Front Neurol. 2017;8:473.","journal-title":"Front Neurol"},{"key":"257_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/ftd.0000000000000546","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526\u201348.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"257_CR33","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1365-2923.2008.03030.x","volume":"42","author":"S Mamede","year":"2008","unstructured":"Mamede S, Schmidt HG, Penaforte JC. Effects of reflective practice on the accuracy of medical diagnoses. Med Educ. 2008;42(5):468\u201375.","journal-title":"Med Educ"},{"issue":"8","key":"257_CR34","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1111\/epi.16594","volume":"61","author":"BN Blond","year":"2020","unstructured":"Blond BN, Hirsch LJ, Mattson RH. Misperceptions on the chance of seizure freedom with antiseizure medications after two failed trials. Epilepsia. 2020;61(8):1789\u201390.","journal-title":"Epilepsia"},{"key":"257_CR35","doi-asserted-by":"publisher","first-page":"E131","DOI":"10.1055\/a-0621-8559","volume":"2","author":"M Burkhardt","year":"2018","unstructured":"Burkhardt M, Bacher M, Kornmeier R, Kurth C, Staack AM, Steinhoff BJ. The general and social health long-term outcome of adult epilepsy patients at the Kork Epilepsy Center. Neurol Int Open. 2018;2:E131-5.","journal-title":"Neurol Int Open"},{"key":"257_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00981-w","author":"P Klein","year":"2024","unstructured":"Klein P, Kaminski RM, Koepp M, L\u00f6scher W. New epilepsy therapies in development. Nat Rev Drug Discov. 2024;23:682\u2013708.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"257_CR37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/nejm200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"257_CR38","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1111\/epi.16720","volume":"61","author":"JA Witt","year":"2020","unstructured":"Witt JA, Nass RD, Baumgartner T, von Wrede R, Elger CE, Surges R, et al. Does the accumulated antiepileptic drug load in chronic epilepsy reflect disease severity? Epilepsia. 2020;61(12):2685\u201395.\u00a0","journal-title":"Epilepsia"},{"key":"257_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2023.107242","volume":"197","author":"DA Becker","year":"2023","unstructured":"Becker DA, Demko SA. Dose reduction and discontinuation of concomitant antiseizure medications after initiating cenobamate: a retrospective review. Epilepsy Res. 2023;197:107242.","journal-title":"Epilepsy Res"},{"issue":"8","key":"257_CR40","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1111\/epi.17662","volume":"64","author":"WE Rosenfeld","year":"2023","unstructured":"Rosenfeld WE, Ferrari L, Kerr WT, Sperling MR. Sudden unexpected death in epilepsy during cenobamate clinical development. Epilepsia. 2023;64(8):2108\u201315.","journal-title":"Epilepsia"},{"key":"257_CR41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.seizure.2021.10.024","volume":"93","author":"JH Cross","year":"2021","unstructured":"Cross JH, Galer BS, Gil-Nagel A, Devinsky O, Ceulemans D, Lagae L,\u00a0et al. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 2021;93:154\u20139.","journal-title":"Seizure"},{"key":"257_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.seizure.2024.04.004","volume":"118","author":"S Mulheron","year":"2024","unstructured":"Mulheron S, Leahy TP, McStravick M, Doran R, Delanty N. A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: a systematic review and network meta-analysis. Seizure. 2024;118:80\u201390.","journal-title":"Seizure"},{"key":"257_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17874","author":"Y Novitskaya","year":"2023","unstructured":"Novitskaya Y, Sch\u00fctz E, Metternich B, Schulze-Bonhage A, Hirsch M. Add-on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: a prospective observational study. Epilepsia. 2024;65:630\u2013640.\u00a0","journal-title":"Epilepsia"},{"issue":"12","key":"257_CR44","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1111\/epi.17092","volume":"62","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Krauss GL, et al. Post-hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia. 2021;62(12):3016\u201328.","journal-title":"Epilepsia"},{"issue":"5","key":"257_CR45","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/epi4.12998","volume":"9","author":"EC Wirrell","year":"2024","unstructured":"Wirrell EC, Lagae L, Scheffer IE, Cross JH, Specchio N, Strzelczyk A. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice. Epilepsia Open. 2024;9(5):1643\u201357.\u00a0","journal-title":"Epilepsia Open"}],"container-title":["Acta Epileptologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42494-026-00257-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42494-026-00257-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42494-026-00257-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T23:03:22Z","timestamp":1780268602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42494-026-00257-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["257"],"URL":"https:\/\/doi.org\/10.1186\/s42494-026-00257-3","relation":{},"ISSN":["2096-9384","2524-4434"],"issn-type":[{"value":"2096-9384","type":"print"},{"value":"2524-4434","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BJS: Advisory and consulting honoraria: Angelini Pharma, Jazz\/GW Pharmaceuticals, Neuraxpharm, Polpharm Speaker\u2019s honoraria: Angelini, Desitin, German Neurological Society, Eisai, Medscape, Neuraxpharm, UCB. Research support: Eisai, European Union, Jannsen-Cilag, Jazz\/GW Pharmaceuticals, Neuraxpharm, SK Life Sciences, UCB, Zogenix. JPL: Full-time employee of Angelini Pharma. Advisory and consulting honoraria: Angelini Pharma, Jazz\/GW Pharmaceuticals, Precisis, Roche Diagnostics, UCB. Speaker\u2019s honoraria: Al Jazeera, Angelini Pharma, Arvelle Therapeutics, Desitin, Eisai, Pfizer, GSK, UCB. Research support: UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}